Bayer Avelox resistant CAP
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bayer's quinolone antibiotic Avelox (moxifloxacin) expands its community-acquired pneumonia indication to include penicillin-resistant strains of Streptococcus pneumoniae via a Feb. 28 supplemental approva